Toripalimab: First Global Approval
- 109 Downloads
Toripalimab, a recombinant, humanized programmed death receptor-1 (PD-1) monoclonal antibody that binds to PD-1 and prevents binding of PD-1 with programmed death ligands 1 (PD-L1) and 2 (PD-L2), is being developed by Shanghai Junshi Bioscience Co., Ltd in China for the treatment of various cancers. In December 2018, based on positive efficacy results of a phase 2 trial and safety data from several clinical studies, toripalimab received conditional approval in China for the treatment of unresectable or metastatic melanoma that has failed previous systemic therapy. This article summarizes the milestones in the development of toripalimab leading to this first global approval for the treatment of unresectable or metastatic melanoma.
Compliance with Ethical Standards
The preparation of this review was not supported by any external funding.
Conflict of interest
During the peer review process the manufacturer of the agent under review was offered an opportunity to provide information for the article. Changes resulting from any information or comments received were made by the authors on the basis of scientific completeness and accuracy. Susan Keam is a salaried employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest.
- 1.National Medical Products Administration. The first domestic PD-1 antibody drug, treipril monoclonal antibody injection, was approved for marketing [media release]. 17 Dec 2018.Google Scholar
- 2.Shanghai Junshi Biosciences Co. Ltd. China’s first self-developed PD-1 monoclonal antibody, Treripril monoclonal antibody, was approved for marketing, and Junshi Biotechnology promoted China’s accelerated entry into a new era of tumor immunotherapy [media release]. 17 Dec 2018. http://junshipharma.com/News.html.
- 4.Shanghai Junshi Biosciences Co. Ltd. Therapeutic areas: immuno-oncology: JS001 (toripalimab, anti-PD-1 mAb); 2019. http://www.junshipharma.com/en/Treatment.html. Accessed 9 Jan 2019.
- 5.Shanghai Junshi Bioscience Co. Ltd. Toripalimab monoclonal antibody injection: Chinese prescribing information; 2019.Google Scholar
- 6.Hogan Lovells. The China Food and Drug Administration pushes forward on conditional approval and compassionate use of new drugs [media release]. 17 Jan 2018. https://www.lexology.com/library/detail.aspx?g=73ce9342-8178-4b42-9c31-389edf0278c1.
- 7.Chi Z, Tang B, Sheng X, et al. A phase II study of JS001, a humanized PD-1 mAb, in patients with advanced melanoma in China [abstract no. 9539]. J Clin Oncol. 2018;36(15 Suppl.).Google Scholar
- 9.Hutchison China MediTech Ltd. Chi-Med enters into multiple collaborations to evaluate combinations of surufatinib and fruquintinib with PD-1 checkpoint inhibitors [media release]. 29 Nov 2018.Google Scholar
- 10.CSPC Pharmaceutical Group Ltd. Product co-development and strategic collaboration agreement [media release]. 10 Jul 2018.Google Scholar
- 11.Shanghai Junshi Biosciences. Shanghai Junshi Biosciences Co., Ltd global offering; 2018. http://www.junshipharma.com/en/Investor-314.html. Accessed 21 Jan 2019.
- 13.Wang FH, Ren C, Zhang Y, et al. Phase Ia study of a humanized anti-PD-1 monoclonal antibody (JS001) in Chinese patients with refractory solid tumors [abstract no. 1186P]. Ann Oncol. 2017;28(Suppl. 5):v420–1.Google Scholar
- 14.Guo J, Sheng X, Si L, et al. A phase Ib study of JS001, a humanized IgG4 mAb against programmed death-1 (PD-1) combination with axitinib in patients with metastatic mucosal melanoma [abstract no. 9528]. J Clin Oncol. 2018;36(15 Suppl.).Google Scholar
- 15.Xu R, Wang FH, Feng FJ, et al. Recombinant humanized anti-PD-1 monoclonal antibody (JS001) in patients with refractory/metastatic nasopharyngeal carcinoma: preliminary results of an open-label phase II clinical study [abstract no. 1150P]. Ann Oncol. 2018;29(Suppl. 8):viii409.Google Scholar
- 16.Sheng X, Chi Z, Cui C, et al. Preliminary results from patients with metastatic urothelial carcinoma (UC) in a phase 2 study of JS001, an anti-PD-1 monoclonal antibody [abstract no. e16505]. J Clin Oncol. 2018;36(15 Suppl.).Google Scholar
- 17.Xu RH, Wang F, Shi J, et al. Recombinant humanized anti-PD-1 monoclonal antibody (JS001) as salvage treatment for advanced esophageal squamous cell carcinoma: preliminary results of an open-label, multi-cohort, phase Ib/II clinical study [abstract no. 116]. J Clin Oncol. 2018;36(4 Suppl.).Google Scholar
- 18.Xu RH, Wang F, Xu N, et al. Recombinant humanized anti-PD-1 monoclonal antibody (JS001) as salvage treatment for advanced gastric adenocarcinoma: preliminary results of an open-label, multi-cohort, phase Ib/II clinical study [abstract no. 108]. J Clin Oncol. 2018;36(4 Suppl.).Google Scholar
- 19.Bian L, Zhang H, Wang T, et al. A phase I study of JS001, a humanized PD-1mAb in patients with advanced triple negative breast cancer [abstract no. e15093]. J Clin Oncol. 2018;36(15 Suppl.).Google Scholar
- 20.Yang S, Yang J, Han X, et al. Effect of JS001, a monoclonal antibody targeting programed death-1 (PD-1), on responses and disease control in patients with advanced or refractory alveolar soft part sarcoma: results from a phase 1 trial [abstract no. 11572]. J Clin Oncol. 2018;36(15 Suppl.).Google Scholar
- 21.Zhang P, Lu M, Li J. Efficacy and safety of PD-1 blockade with JS001 in patients with advanced neuroendocrine neoplasms: a non-randomized, open-label, phase Ib trial [abstract no. 1309O]. Ann Oncol. 2018;29(Suppl. 8):viii468.Google Scholar